DE69624695D1 - VERFAHREN ZUR SPEZIFISCHEN KOPPLUNG EINER SCHUTZGRUPPE AN DAS 5'-ENDE EINES mRNA-FRAGMENTES UND DIE HERSTELLUNG VON mRNA UND VOLLSTÄNDIGER cDNA - Google Patents

VERFAHREN ZUR SPEZIFISCHEN KOPPLUNG EINER SCHUTZGRUPPE AN DAS 5'-ENDE EINES mRNA-FRAGMENTES UND DIE HERSTELLUNG VON mRNA UND VOLLSTÄNDIGER cDNA

Info

Publication number
DE69624695D1
DE69624695D1 DE69624695T DE69624695T DE69624695D1 DE 69624695 D1 DE69624695 D1 DE 69624695D1 DE 69624695 T DE69624695 T DE 69624695T DE 69624695 T DE69624695 T DE 69624695T DE 69624695 D1 DE69624695 D1 DE 69624695D1
Authority
DE
Germany
Prior art keywords
mrna
pct
specific coupling
production
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69624695T
Other languages
English (en)
Other versions
DE69624695T2 (de
Inventor
Irena Nicolaevna Merenkova
Milne Edwards Gabriel Dumas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Serono Genetics Institute SA
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9505221A external-priority patent/FR2733765B1/fr
Application filed by Serono Genetics Institute SA, Genset SA filed Critical Serono Genetics Institute SA
Application granted granted Critical
Publication of DE69624695D1 publication Critical patent/DE69624695D1/de
Publication of DE69624695T2 publication Critical patent/DE69624695T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69624695T 1995-05-02 1996-04-29 VERFAHREN ZUR SPEZIFISCHEN KOPPLUNG EINER SCHUTZGRUPPE AN DAS 5'-ENDE EINES mRNA-FRAGMENTES UND DIE HERSTELLUNG VON mRNA UND VOLLSTÄNDIGER cDNA Expired - Fee Related DE69624695T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9505221A FR2733765B1 (fr) 1995-05-02 1995-05-02 Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm
FR9509467A FR2733762B1 (fr) 1995-05-02 1995-08-03 Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
PCT/FR1996/000651 WO1996034981A2 (fr) 1995-05-02 1996-04-29 METHODE DE COUPLAGE SPECIFIQUE DE LA COIFFE DE L'EXTREMITE 5' D'UN FRAGMENT D'ARNm ET PREPARATION D'ARNm ET D'ADNc COMPLET

Publications (2)

Publication Number Publication Date
DE69624695D1 true DE69624695D1 (de) 2002-12-12
DE69624695T2 DE69624695T2 (de) 2003-07-31

Family

ID=26231928

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624695T Expired - Fee Related DE69624695T2 (de) 1995-05-02 1996-04-29 VERFAHREN ZUR SPEZIFISCHEN KOPPLUNG EINER SCHUTZGRUPPE AN DAS 5'-ENDE EINES mRNA-FRAGMENTES UND DIE HERSTELLUNG VON mRNA UND VOLLSTÄNDIGER cDNA

Country Status (12)

Country Link
US (1) US6022715A (de)
EP (1) EP0824598B1 (de)
JP (1) JPH11510364A (de)
AT (1) ATE227346T1 (de)
AU (1) AU719217B2 (de)
CA (1) CA2220045C (de)
DE (1) DE69624695T2 (de)
DK (1) DK0824598T3 (de)
ES (1) ES2186778T3 (de)
FR (1) FR2733762B1 (de)
PT (1) PT824598E (de)
WO (1) WO1996034981A2 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766891A (en) 1994-12-19 1998-06-16 Sloan-Kettering Institute For Cancer Research Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
JP3441899B2 (ja) * 1996-11-01 2003-09-02 理化学研究所 完全長ｃＤＮＡライブラリーの作成方法
WO1998056943A1 (en) 1997-06-12 1998-12-17 Sloan-Kettering Institute For Cancer Research Covalent joining of dna strands to rna strands catalyzed by vaccinia topoisomerase
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
DE69835777T2 (de) * 1997-08-01 2007-09-06 Serono Genetics Institute S.A. 5' EST's für sekretierte Proteine, die in verschiedenen Geweben exprimiert werden
AU8555798A (en) * 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
JP2001512014A (ja) * 1997-08-01 2001-08-21 ジェンセット 脳組織から同定された分泌タンパク質の５’ｅｓｔ
AU8554798A (en) * 1997-08-01 1999-02-22 Genset 5'ests for non tissue specific secreted proteins
AU8555198A (en) * 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in prostate
EP0994899A2 (de) * 1997-08-01 2000-04-26 Serono Genetics Institute S.A. 5' ests für sekretierte proteine, die im endoderm exprimiert werden
DK1378571T3 (da) * 1997-08-01 2011-04-04 Merck Serono Biodevelopment 5' ESTs for sekreterede proteiner udtrykt i forskellige væv
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
AU9645598A (en) * 1997-10-22 1999-05-10 Helix Research Institute Method for screening full-length cdna clones
US6573068B1 (en) 1997-11-13 2003-06-03 Genset, S. A. Claudin-50 protein
US20060286639A1 (en) * 1997-11-13 2006-12-21 Serono Genetics Institute S.A. Complementary DNAs encoding proteins with signal peptides
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
EP1903111A3 (de) * 1997-11-13 2008-07-02 Serono Genetics Institute S.A. Erweiterte cDNA für sekretierte Proteine
WO1999040189A2 (en) * 1998-02-09 1999-08-12 Genset Cdnas encoding secreted proteins
CA2302644A1 (en) * 1997-11-13 1999-05-27 Genset S.A. Extended cdnas for secreted proteins
ATE440951T1 (de) * 1997-12-17 2009-09-15 Serono Genetics Inst Sa Verlängerte cdns, die für sekretierte proteine kodieren
US7223727B2 (en) 1998-04-09 2007-05-29 Serono Genetics Institute S.A. GSSP4 polynucleotides and polypeptides and uses thereof
EP1068312A2 (de) * 1998-04-09 2001-01-17 Genset Humane 5' est's und kodierte proteine
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
AU772243B2 (en) 1998-11-04 2004-04-22 Genset Genomic and complete cDNA sequences of human adipocyte-specific APM1 and biallelic markers thereof
US6455280B1 (en) 1998-12-22 2002-09-24 Genset S.A. Methods and compositions for inhibiting neoplastic cell growth
CA2359757A1 (en) 1999-02-10 2000-08-17 Genset S.A. Polymorphic markers of the lsr gene
EP1586645A3 (de) 1999-02-25 2006-02-22 Ceres Incorporated DNA-Fragmente mit bestimmter Sequenz und die dadurch kodierte Polypeptide
AU3397800A (en) * 1999-03-19 2000-10-09 Invitrogen Corporation Methods of obtaining full-length nucleic acid sequences using (e. coli) topoisomerase iii and its homologs
AU3763200A (en) * 1999-03-19 2000-10-09 Genetics Institute Inc. Primers-attached vector elongation (pave): a 5'-directed cdna cloning strategy
US7485715B2 (en) 1999-06-18 2009-02-03 Ceres, Inc. Sequence-determined DNA encoding AP2 domain polypeptides
US7479555B2 (en) 1999-07-21 2009-01-20 Ceres, Inc. Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
EP1261724A4 (de) 2000-02-25 2004-08-18 Invitrogen Corp Topoisomerase linker-vermittelte amplifizierungsverfahren
US6387624B1 (en) * 2000-04-14 2002-05-14 Incyte Pharmaceuticals, Inc. Construction of uni-directionally cloned cDNA libraries from messenger RNA for improved 3′ end DNA sequencing
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP1313851B1 (de) 2000-08-21 2006-01-04 Invitrogen Corporation Methoden und reagenzien für molekulares klonieren
US6875907B2 (en) 2000-09-13 2005-04-05 Pioneer Hi-Bred International, Inc. Antimicrobial peptides and methods of use
AU2002248173B2 (en) 2000-12-08 2007-04-26 Invitrogen Corporation Compositions and methods for rapidly generating recombinant nucleic acid molecules
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
MXPA04002817A (es) 2001-09-27 2004-07-05 Pioneer Hi Bred Int Polinucleotidos de fitato y metodos de uso.
US7358419B2 (en) 2002-04-08 2008-04-15 Pioneer Hi-Bred International, Inc. Enhanced silk exsertion under stress
US20050250100A1 (en) * 2002-06-12 2005-11-10 Yoshihide Hayashizaki Method of utilizing the 5'end of transcribed nucleic acid regions for cloning and analysis
CA2520811C (en) * 2003-03-28 2013-05-28 Japan As Represented By Director General Of National Rehabilitation Center For Persons With Disabilities Method of cdna synthesis
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
GB0417887D0 (en) 2004-08-11 2004-09-15 Ares Trading Sa Protein
CN101535475B (zh) * 2006-09-11 2012-08-08 国立大学法人大阪大学 微量mRNA的扩增方法及其应用
EP2215238A2 (de) 2007-11-20 2010-08-11 Pioneer Hi-Bred International Inc. Ethylen-signalgebungsgene aus mais und deren modulation für verbesserte stresstoleranz in pflanzen
US20100035249A1 (en) * 2008-08-05 2010-02-11 Kabushiki Kaisha Dnaform Rna sequencing and analysis using solid support
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
WO2011017492A2 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3682905T (lt) 2011-10-03 2022-02-25 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai ir nukleorūgštys bei jų naudojimas
CA2853449A1 (en) 2011-10-25 2013-05-02 Pioneer Hi-Bred International, Inc. Methods to alter plant cell wall composition for improved biofuel production and silage digestibility
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
EP2684954A1 (de) 2012-07-10 2014-01-15 Lexogen GmbH 5'-schutzabhängige Verstärkung
US9422602B2 (en) * 2012-08-15 2016-08-23 Bio-Rad Laboratories, Inc. Methods and compositions for determining nucleic acid degradation
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
EP2971033B8 (de) 2013-03-15 2019-07-10 ModernaTX, Inc. Herstellungsverfahren zur herstellung von rna-transkripten
EP2971165A4 (de) 2013-03-15 2016-11-23 Moderna Therapeutics Inc Entfernung von dna-fragmenten in mrna-herstellungsverfahren
CA2903297A1 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Modulation of acc deaminase expression
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2983804A4 (de) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ionenaustauschreinigung von mrna
SI3019619T1 (sl) 2013-07-11 2021-12-31 Modernatx, Inc. Sestave, ki zajemajo sintetične polinukleotide, ki kodirajo proteine, pozvezane s crispr, in sintetične sgrna, ter metode uporabe
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
US11479766B2 (en) * 2013-12-05 2022-10-25 New England Biolabs, Inc. Methods for labeling a population of RNA molecules
JP2017522028A (ja) 2014-07-16 2017-08-10 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 環状ポリヌクレオチド
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
ES2908449T3 (es) 2015-09-17 2022-04-29 Modernatx Inc Polinucleótidos que contienen una región de cola estabilizadora
US20190218546A1 (en) 2015-10-16 2019-07-18 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
US11312991B2 (en) 2016-01-27 2022-04-26 Kabushiki Kaisha Dnaform Method for decoding base sequence of nucleic acid corresponding to end region of RNA and method for analyzing DNA element
MX2019002904A (es) 2016-09-14 2019-09-26 Modernatx Inc Composiciones de arn de alta pureza y métodos para su preparación.
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
WO2023127774A1 (ja) * 2021-12-28 2023-07-06 株式会社ダナフォーム 遺伝子包含体の検出方法及び検出用キット
WO2023237703A1 (en) 2022-06-09 2023-12-14 Vestlandets Innovasjonsselskap As Method of characterizing capped rna

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661450A (en) * 1983-05-03 1987-04-28 Molecular Genetics Research And Development Limited Partnership Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides
US4710566A (en) * 1984-12-27 1987-12-01 Yale University Purification of the messenger RNA cap-binding protein
US5273879A (en) * 1987-07-23 1993-12-28 Syntex (U.S.A.) Inc. Amplification method for polynucleotide assays
US5219989A (en) * 1988-12-13 1993-06-15 Mcgill University Bifunctional protein for the isolation of capped mRNA
CA2005252C (en) * 1988-12-13 2001-07-17 Nahum Sonenberg Isolation of full-length cdna clones and capped mrna
US5324829A (en) * 1988-12-16 1994-06-28 Ortho Diagnostic Systems, Inc. High specific activity nucleic acid probes having target recognition and signal generating moieties
JP3315439B2 (ja) * 1992-07-21 2002-08-19 住友電気工業株式会社 細胞特異的ｃＤＮＡの分離法及びライブラリー作製法
JP3337748B2 (ja) * 1992-09-25 2002-10-21 財団法人神奈川科学技術アカデミー 完全長ｃＤＮＡの合成方法、その中間体の製造方法及び完全長ｃＤＮＡを含む組換えベクターの製造方法

Also Published As

Publication number Publication date
DE69624695T2 (de) 2003-07-31
CA2220045A1 (fr) 1996-11-07
DK0824598T3 (da) 2003-03-10
JPH11510364A (ja) 1999-09-14
EP0824598A2 (de) 1998-02-25
AU719217B2 (en) 2000-05-04
AU5982996A (en) 1996-11-21
FR2733762A1 (fr) 1996-11-08
PT824598E (pt) 2003-03-31
WO1996034981A3 (fr) 1997-01-03
FR2733762B1 (fr) 1997-08-01
WO1996034981A2 (fr) 1996-11-07
ATE227346T1 (de) 2002-11-15
US6022715A (en) 2000-02-08
EP0824598B1 (de) 2002-11-06
ES2186778T3 (es) 2003-05-16
CA2220045C (fr) 2001-10-30

Similar Documents

Publication Publication Date Title
DE69624695D1 (de) VERFAHREN ZUR SPEZIFISCHEN KOPPLUNG EINER SCHUTZGRUPPE AN DAS 5'-ENDE EINES mRNA-FRAGMENTES UND DIE HERSTELLUNG VON mRNA UND VOLLSTÄNDIGER cDNA
DE69716767D1 (de) Verfahren zur herstellung von tolterodin
DE69527876D1 (de) Zwischenprodukte für die Herstellung von Pyrazoloazolen als fotografische Kuppler, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69823662D1 (de) 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen
DE60011396D1 (de) Verfahren zur herstellung von iopamidol
ATE204905T1 (de) Verfahren zur herstellung von äthylalkohol
ATE187440T1 (de) Verfahren zur herstellung von substituierten 3- aminobenzonitrilen
ATE253568T1 (de) Verfahren zur herstellung von citalopram
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE252543T1 (de) Verfahren zur herstellung chiraler (s)-2,3- disubstituierter 1-propylamin-derivate
DE59506870D1 (de) Verfahren zur Herstellung von Polyamiden auf Basis von alpha,omega-Dinitrilen
DE69518192D1 (de) Verfahren zur Herstellung von N-Alkyl-N-Pyridinyl-1H-Indol-1-Aminen
ATE155771T1 (de) Verfahren zur herstellung von ceramiden
DE59705787D1 (de) Verfahren zur herstellung von n,n'-dialkylperylen-3,4,9,10-tetracarbonsäurediimiden
ATE308571T1 (de) Verfahren zur herstellung von hydrierten aromatischen polymerzusammensetzungen
ATE234288T1 (de) Verfahren zur herstellung eines buthylthuio- isochinolinderivates und zwischenprodukte dafür
ATE205473T1 (de) Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
ATE235461T1 (de) Verfahren zur herstellung von 3-cyano-2,4- dihalogen-5-fluor-benzoesäuren
ATE215552T1 (de) Verfahren zur herstellung von ivermectin
DE69515053D1 (de) Verfahren zur herstellung von furosemide
IL160047A (en) Method for the production of 6-(4- chlorophenyl)- 2,2- dimethyl- 7- phenyl- 2,3- dihydro-1h -pyrrolizin- 5-ylacetic acid
DE69504188D1 (de) Verfahren zur herstellung von 5-amino-1,3-dioxanen
ATE281428T1 (de) Verfahren zur herstellung von methoxyimino- essigsäureamiden
ATE325111T1 (de) Verfahren zur herstellung von 15-pentadecanolid
ATE231159T1 (de) Neues verfahren zur herstellung von etoposid

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee